Netherlands Diabetes Device Market: From €343M to €642M — Remote Care and Aging Drive the Boom

A patient, a pump and a phone: how diabetes care is changing in the Netherlands

On a cloudy morning in Amsterdam, a 74-year-old pensioner checks his phone. A continuous glucose monitor (CGM) clipped discreetly to his arm is streaming glucose readings to an app that his practice nurse can review before their weekly teleconsultation. He adjusts his insulin dose after a prompt from his care team, skips an unnecessary clinic visit, and heads out to meet a friend — confident that the device will alert him if levels fall or spike.

That scene is increasingly typical. The Netherlands — with an ageing population, strong primary-care networks and fast telehealth adoption — is witnessing a structural shift in how diabetes is monitored and managed. The market for diabetes devices here is growing fast: from US$ 343.4 million in 2023 to a forecast US$ 641.7 million by 2032, a compound annual growth rate of 7.2% (2024–2032).

Market snapshot & why it matters

Diabetes remains one of the country’s major public-health challenges. In 2021 roughly 1.1 million people (about 6.4% of adults) were living with diabetes in the Netherlands, and around 58,000 new cases are reported annually — predominantly type 2. Complications from poorly controlled diabetes remain a leading cause of morbidity and mortality, making effective monitoring and insulin delivery technologies critical.

Devices — from portable blood glucose meters to sophisticated insulin pumps and CGMs — reduce the burden of self-management, lower complication risks and enable remote monitoring. As healthcare delivery pivots toward prevention, early intervention and virtual care, demand for diabetes devices is becoming a health-system priority as well as a commercial growth area.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Drivers of growth: ageing, telehealth and technology

1. Ageing population and rising prevalence

The Netherlands’ demographic profile — with higher diabetes incidence among older age groups (notably those aged 70–79) — is a core demand driver. Age-related insulin resistance, sedentary lifestyles and comorbidities create persistent demand for both monitoring and delivery devices (insulin pens and pumps).

2. Telehealth and remote monitoring adoption

COVID-era digital health acceleration has left lasting change. Clinicians and patients now favour remote glucose monitoring and asynchronous data review. CGMs coupled with cloud platforms allow clinicians to triage patients, optimise regimens and reduce unnecessary hospital visits — a powerful efficiency argument for payers and providers.

3. Technology innovation & product launches

Manufacturers are pushing innovation: more user-friendly CGMs, multi-site wearable sensors, smarter insulin pumps, and interoperable platforms that integrate with electronic health records. Recent launches (e.g., Dexcom’s Dexcom ONE+ in Europe) illustrate how device sophistication—smaller form factors, multi-site wearability and improved accuracy—stimulates adoption.

4. Policy and care models that prioritise outcomes

Dutch primary-care emphasis on chronic-disease management, combined with payer interest in cost-effective remote care, creates a receptive environment for devices that demonstrably reduce complications and hospitalisations.

Market challenges: reimbursement, behaviour and equity

Growth is not automatic. Several barriers temper uptake:

Reimbursement complexities: Coverage varies across insurers for advanced CGMs and pumps, especially for people with type 2 diabetes who historically were less likely to qualify for high-cost devices. Wider reimbursement criteria will be essential to scale adoption.

Patient and clinician behaviour: Not all patients—or clinicians—adopt new workflows readily. Training, change management and digital literacy (especially among older adults) remain practical hurdles.

Cost and device equity: Advanced devices carry higher price tags. Ensuring equitable access across socio-economic groups will require targeted policy and subsidy mechanisms.

Data governance & interoperability: Patient data flows must be secure, and devices must integrate with Dutch healthcare IT systems to unlock clinical value. Fragmentation risks dampen clinician willingness to adopt device ecosystems.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market segmentation: where the dollars flow

The industry divides into four device categories and three end-use channels:

By device type

Self-monitoring blood glucose (SMBG) devices: Still foundational, especially for insulin-treated patients and those without CGMs.

Continuous glucose monitoring (CGM) devices: Fastest growing segment due to real-time data and remote-care compatibility.

Insulin pumps: Offering tighter control and lifestyle flexibility; uptake increases as pumps become smaller and smarter.

Insulin pens: Dominant for many type-2 patients because of simplicity and lower cost.

By end user

Hospitals: Use a mix of pumps and CGMs for inpatient and specialist care.

Diagnostics centres: SMBG and CGM analytics are integrated into diabetes clinics.

Homecare: The largest growth frontier—wearables, connected pens and apps that enable at-home self-management.

Competitive landscape & key players

Global leaders and medtech specialists dominate the Dutch market: Dexcom, Abbott, Medtronic, Roche, BD, Terumo and insulin manufacturers such as Eli Lilly (in insulin delivery partnerships). Key dynamics:

Dexcom — CGM innovations and recent European rollouts (e.g., Dexcom ONE+ with multi-site wearability) broaden addressable populations.

Abbott — Freestyle Libre systems continue to push price-performance and patient uptake.

Medtronic — Strength in integrated pump-sensor systems and hospital partnerships.

Roche — Broad diabetes portfolio including SMBG and advanced analytics.

Eli Lilly — Active in insulin therapies and connected pen ecosystems.

Local distributors and diabetes-care service providers play a critical role in education, training and after-sales support — factors that heavily influence adoption in a market focused on outcomes.

Recent market moves & regulatory context

Product launches and incremental approvals (e.g., Roche’s Accu-Chek Guide) show an active product pipeline. The Dutch healthcare system’s emphasis on outcomes and integrated chronic-care pathways makes real-world evidence and cost-effectiveness data decisive for broader rollout.

Regulators and insurers are increasingly receptive to remote monitoring that reduces long-term complications. However, broader coverage for CGMs and pumps—especially for type-2 populations—will likely be staged and evidence-dependent.

Outlook: integration, affordability and population health impact

At a 7.2% CAGR, the Netherlands diabetes-device market is set to nearly double by 2032. But the real opportunity lies beyond unit sales: in integration of devices into care pathways that reduce amputations, renal disease and avoidable hospital admissions. Successful scaling will depend on three levers:

Evidence generation — strong health-economic data to support reimbursement for CGMs and pumps in broader patient cohorts.

Digital integration — interoperable platforms that allow clinicians to act on device data efficiently.

Access programmes — pricing, subsidies or risk-sharing contracts that widen access for older and lower-income patients.

If policymakers, clinicians and industry align, the forecast is not just a market success story: it becomes a public-health victory — fewer complications, lower long-term costs and better quality of life for the Netherlands’ growing population of people with diabetes.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.